|Positive WB detected in||rat testis tissue, HeLa cells|
|Western Blot (WB)||WB : 1:200-1:1000|
|Sample-dependent, check data in validation data gallery|
16039-1-AP targets TUSC3 in WB,ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||TUSC3 fusion protein Ag8912|
|Full Name||tumor suppressor candidate 3|
|Calculated molecular weight||347 aa, 40 kDa|
|Observed molecular weight||35-40 kDa|
|GenBank accession number||BC010370|
|Gene ID (NCBI)||7991|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
TUSC3 (tumor suppressor candidate 3), originally named N33, is a potential tumor supressor gene. Decreased expression of TUSC3 has been found in various cancers, including prostate cancer, pancreas cancer and ovary cancer. TUSC3 also known as OST3A, is identified as a part of the oligosaccharyl-transferase (OST) complex and plays a crucial role in protein N-glycosylation. TUSC3 mutations have been found in families with non-syndromic autosomal recessive mental retardation.
Proc Natl Acad Sci U S A
Mutations in MAGT1 lead to a glycosylation disorder with a variable phenotype.
Mammalian cells lacking either the cotranslational or posttranslocational oligosaccharyltransferase complex display substrate-dependent defects in asparagine linked glycosylation.
J Cell Biol
Oxidoreductase activity is necessary for N-glycosylation of cysteine-proximal acceptor sites in glycoproteins.
miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC.